Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10692MR)

This product GTTS-WQ10692MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10692MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6895MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ8331MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ15480MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ6698MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ1609MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ1161MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ12473MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ15824MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb14045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW